Peter Lawson
Stock Analyst at Barclays
(2.07)
# 2,932
Out of 5,179 analysts
102
Total ratings
41.3%
Success rate
-7.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Lawson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ONC BeOne Medicines AG | Maintains: Overweight | $394 → $405 | $283.03 | +43.09% | 3 | Feb 27, 2026 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $19 → $22 | $23.49 | -6.34% | 5 | Nov 4, 2025 | |
| INCY Incyte | Maintains: Overweight | $90 → $101 | $90.30 | +11.85% | 1 | Oct 29, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $40 | $30.46 | +31.32% | 1 | Sep 4, 2025 | |
| SDGR Schrödinger | Initiates: Overweight | $25 | $11.08 | +125.63% | 1 | Aug 14, 2025 | |
| REPL Replimune Group | Downgrades: Equal-Weight | $17 → $3 | $7.22 | -58.45% | 4 | Jul 23, 2025 | |
| EXEL Exelixis | Maintains: Equal-Weight | $29 → $40 | $41.53 | -3.68% | 6 | Jul 10, 2025 | |
| MGNX MacroGenics | Maintains: Overweight | $8 → $3 | $2.93 | +2.39% | 9 | May 14, 2025 | |
| FATE Fate Therapeutics | Maintains: Overweight | $10 → $2 | $1.17 | +70.94% | 4 | May 14, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | $5 → $10 | $5.48 | +82.48% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $3.51 | +13.96% | 7 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $22 → $6 | $11.42 | -47.46% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $52 | $29.44 | +76.63% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $11 | $7.74 | +42.12% | 1 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $16 | $10.10 | +58.42% | 8 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $4.31 | +248.03% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $14 | $20.28 | -30.97% | 7 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $3 | $1.32 | +127.27% | 5 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $3 | $0.99 | +203.49% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $4 | $1.40 | +185.71% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $60 | $92.51 | -35.14% | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $17 | $9.60 | +77.08% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $31 | $14.76 | +110.03% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $13 | $19.26 | -32.50% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $3.05 | +63.93% | 4 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3.5 | $4.52 | -22.57% | 4 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $355 → $365 | $117.67 | +210.19% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $46 | $29.43 | +56.30% | 2 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $450 | $68.66 | +555.40% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $17 → $45 | $2.23 | +1,917.94% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 → $45 | $45.75 | -1.64% | 2 | Jan 23, 2018 |
BeOne Medicines AG
Feb 27, 2026
Maintains: Overweight
Price Target: $394 → $405
Current: $283.03
Upside: +43.09%
Syndax Pharmaceuticals
Nov 4, 2025
Maintains: Overweight
Price Target: $19 → $22
Current: $23.49
Upside: -6.34%
Incyte
Oct 29, 2025
Maintains: Overweight
Price Target: $90 → $101
Current: $90.30
Upside: +11.85%
IDEAYA Biosciences
Sep 4, 2025
Initiates: Overweight
Price Target: $40
Current: $30.46
Upside: +31.32%
Schrödinger
Aug 14, 2025
Initiates: Overweight
Price Target: $25
Current: $11.08
Upside: +125.63%
Replimune Group
Jul 23, 2025
Downgrades: Equal-Weight
Price Target: $17 → $3
Current: $7.22
Upside: -58.45%
Exelixis
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $29 → $40
Current: $41.53
Upside: -3.68%
MacroGenics
May 14, 2025
Maintains: Overweight
Price Target: $8 → $3
Current: $2.93
Upside: +2.39%
Fate Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $10 → $2
Current: $1.17
Upside: +70.94%
Karyopharm Therapeutics
May 13, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $5.48
Upside: +82.48%
May 12, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $3.51
Upside: +13.96%
May 8, 2025
Maintains: Underweight
Price Target: $22 → $6
Current: $11.42
Upside: -47.46%
May 7, 2025
Maintains: Overweight
Price Target: $66 → $52
Current: $29.44
Upside: +76.63%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $11
Current: $7.74
Upside: +42.12%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $16
Current: $10.10
Upside: +58.42%
May 1, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $4.31
Upside: +248.03%
Apr 23, 2025
Maintains: Overweight
Price Target: $29 → $14
Current: $20.28
Upside: -30.97%
Apr 2, 2025
Maintains: Equal-Weight
Price Target: $11 → $3
Current: $1.32
Upside: +127.27%
Mar 7, 2025
Maintains: Overweight
Price Target: $14 → $3
Current: $0.99
Upside: +203.49%
Feb 27, 2025
Maintains: Overweight
Price Target: $9 → $4
Current: $1.40
Upside: +185.71%
Sep 27, 2024
Maintains: Overweight
Price Target: $54 → $60
Current: $92.51
Upside: -35.14%
Sep 10, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $9.60
Upside: +77.08%
Jul 15, 2024
Maintains: Overweight
Price Target: $20 → $31
Current: $14.76
Upside: +110.03%
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $19.26
Upside: -32.50%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $3.05
Upside: +63.93%
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $4.52
Upside: -22.57%
Aug 6, 2021
Maintains: Underweight
Price Target: $355 → $365
Current: $117.67
Upside: +210.19%
Oct 22, 2020
Upgrades: Overweight
Price Target: $46
Current: $29.43
Upside: +56.30%
Mar 4, 2020
Initiates: Overweight
Price Target: $450
Current: $68.66
Upside: +555.40%
Jan 23, 2018
Upgrades: Buy
Price Target: $17 → $45
Current: $2.23
Upside: +1,917.94%
Jan 23, 2018
Upgrades: Buy
Price Target: $16 → $45
Current: $45.75
Upside: -1.64%